ACADIA Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
ACADIA Pharmaceuticals heeft een totaal eigen vermogen van $577.2M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $976.9M en $399.7M. De EBIT ACADIA Pharmaceuticals is $112.2M waardoor de rentedekking -4.8 is. Het heeft contanten en kortetermijnbeleggingen van $565.3M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | -4.8x |
| Contant | US$565.33m |
| Aandelen | US$577.18m |
| Totaal verplichtingen | US$399.69m |
| Totaal activa | US$976.87m |
Recente financiële gezondheidsupdates
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $788.3M ) ACAD } overtreffen de korte termijn passiva ( $343.9M ).
Langlopende schulden: De kortetermijnactiva ACAD ( $788.3M ) overtreffen de langetermijnschulden ( $55.7M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ACAD is schuldenvrij.
Schuld verminderen: ACAD heeft de afgelopen 5 jaar geen schulden gehad.
Schuldendekking: ACAD heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.
Rentedekking: ACAD heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.